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Introduction
Nephrotic syndrome (NS) is characterized by proteinuria caused 
by disruption of the glomerular filtration barrier (1). It is the sec-
ond most frequent cause of chronic kidney disease before the age 
of 25 years and has an incidence of approximately 2 per 100,000 
individuals (2). Steroid-resistant nephrotic syndrome (SRNS), 
which manifests histologically as focal segmental glomeruloscle-
rosis (FSGS), inescapably results in end-stage renal disease (ESRD) 
through the progressive loss of the filtration barrier. It remains one 
of the most intractable kidney diseases (3). The identification of 
single-gene causes of SRNS and subsequent research on the func-
tion of those genes have helped to assemble the essential compo-
nents of glomerular podocyte function (4–6). SRNS is genetically 
heterogeneous, and more than 50 monogenic genes have been dis-
covered to cause podocyte dysfunction if mutated. These findings 
revealed podocytes as the critical site of pathogenesis in SRNS (5). 
Fascinatingly, the proteins encoded by the genes that are mutated 
in monogenic causes of disease have started to coalesce to protein 
interaction complexes that, through their loss of function, define 
the pathomechanisms of nephrotic syndrome (5).
One of the protein-protein interaction clusters is involved in 
the dynamic control of the actin cytoskeleton, which is essential 
in maintaining the shape and movement of the podocyte foot pro-
cesses, as well as in maintaining cell-cell contacts. More than one 
hundred proteins are involved in the regulation of actin, enabling 
processes such as polymerization and depolymerization, which 
are necessary for foot process formation and lamellipodia forma-
tion in cell culture (7). Interestingly, 15 of the 40 disease-causing 
genes encode proteins that regulate the small Rho-like GTPases 
RhoA, Rac1,and Cdc42, which are the master regulators of actin 
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HM (14) and WES (15) to individuals with SRNS. HM in 1 of the 
affected siblings with SRNS from a consanguineous Turkish fam-
ily (A2438_22) (Figure 1, A and B) yielded 14 candidate regions 
of homozygosity by descent, with a cumulative genomic length 
of approximately 94 Mb (Figure 1C). Using WES, we detected a 
homozygous missense mutation (c.1273C>A; p.Leu425Met, con-
served to Ciona intestinalis) in the advillin gene (AVIL) (RefSeq 
accession number NM 006576.3) (Table 1, Figure 2, A–D, and Sup-
plemental Table 1). The mutation segregated with the affected sta-
tus in this family and was not present homozygously in the Exome 
Aggregation Consortium (ExAC) data set (Table 1). Direct inspec-
tion of sequence alignments from whole-exome data did not yield 
a mutation in any of the 40 known NS genes.
In order to investigate whether AVIL mutations occur in addi-
tional individuals with NS, we examined a worldwide cohort of 
approximately 800 individuals with SRNS by exon resequencing 
of all 19 AVIL-coding exons (Figure 2A) using an approach of mul-
tiplex PCR followed by next-generation sequencing (NGS), which 
we developed (16). In an individual with SRNS from the United 
Kingdom (A913_21), we detected 2 compound heterozygous 
mutations in AVIL: c.404G>A (p.Arg135Gln) and c.1964dupT 
cytoskeleton rearrangement including the Rho GDP disassocia-
tion inhibitor ARHGDIA (8). In addition, actin remodeling has 
also been implicated in NS (9). Defects in actin remodeling may 
be part of the reason why a defect in the podocyte migration rate 
(PMR) in cell culture has been established as a reliable intermedi-
ate phenotype in monogenic forms of SRNS (8, 10–12).
We have recently shown in a cohort of 1,780 families with SRNS 
that 30% of all cases are caused by mutations in 1 of the 26 genes 
known at the time to cause SRNS (13). However, this indicated that 
additional single-gene causes of SRNS must exist that are yet to be 
discovered. Therefore, to identify monogenic causes of SRNS and 
to further understand its pathogenesis, we applied homozygosity 
mapping (HM) and whole-exome sequencing (WES) to individu-
als with SRNS and identified mutations in AVIL as a cause of NS 
and characterized the related pathogenesis (Supplemental Figure 
1; supplemental material available online with this article; https://
doi.org/10.1172/JCI94138DS1).
Results
Mutations of AVIL cause SRNS. To identify monogenic causes 
of SRNS and further understand its pathogenesis, we applied 
Figure 1. Renal histology, pedigree analysis and homozygosity mapping in family A2438 diagnosed with SRNS. (A) Renal histology of individuals with 
AVIL mutation. Renal histology by light microscopy (LM) from individual A2438_22 with PAS staining showed DMS (scale bars: 50 μm). Transmission elec-
tron microscopy (TEM) image from individual A2438_22 showed diffuse foot process effacement (arrowheads). Original magnification, ×7,000. (B) Pedigree 
for index family A2438. Squares represent males, circles females, black symbols indicate affected persons, and white symbols designate unaffected 
persons. The double line indicates the consanguineous family. (C) Homozygosity mapping identified recessive candidate loci. In individual A2438_22 with 
SRNS, nonparametric lod (NPL) scores were calculated and plotted across the human genome. The x axis plots Affymetrix 250K StyI array SNP positions 
on human chromosomes concatenated from p-ter (left) to q-ter (right). Genetic distance is given in centimorgans (cM). Maximum NPL peaks (red circles) 
indicate 14 candidate regions of homozygosity by descent as recessive candidate loci. The AVIL locus (arrowhead) is positioned within one of the maximum 
NPL peaks on chromosome 12q.
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(p.Phe656Valfs*7) (Table 1 and Figure 2, A–D). The 2 heterozygous 
mutations were sequenced after subcloning into a vector plasmid 
by TA cloning, and it was found that the compound heterozygous 
mutations were in trans. (Supplemental Figure 2). In an SRNS 
patient of Turkish descent (A2647_21), we detected 2 compound 
heterozygous mutations in AVIL: c.1337G>A (p.Arg446His) and 
c.1273C>A (p.Leu425Met) (Table 1 and Figure 2, A–D). We further 
confirmed the rarity of the genetic variants identified in the Turk-
ish SRNS patients A2433_22 and A2647_21 by examining and con-
firming their absence from the high-throughput exon-sequencing 
data from approximately 200 SRNS patients of Turkish descent.
The renal histological analyses for individuals A2438_22 and 
A913_21 revealed diffuse mesangial sclerosis (DMS) (Table 1 and 
Figure 1A). The 2 individuals manifested signs of NS before 1 year 
of age and progressed to ESRD before 3 years of age (Table 1). DMS 
is a distinct clinicopathologic entity of severe NS (17) that shares 
a pathogenic spectrum with focal segmental glomerulosclerosis 
(FSGS) (18). It is characterized clinically by early-onset SRNS and 
rapid progression to ESRD. Individual A2438_22 had severe SRNS 
combined with deafness, cataracts, microcephaly, and intellec-
tual disability. Individual A913_21 had severe NS combined with 
retinal dystrophy and pervasive refusal syndrome. A spectrum 
ranging from severe early-onset NS with DMS to a later-onset 
form with FSGSwas observed here, as has also been described in 
phospholi pase C ϵ1 (PLCE1) mutations (19).
In total, we detected 4 different homozygous or compound 
heterozygous mutations of AVIL in 3 families affected by NS 
(Table 1, Figure 1, A–D, and Supplemental Figure 1, A–C). Copy 
number variation (CNV) analysis of these affected individuals 
revealed no deleterious CNV. Mutation segregation was consis-
tent with recessive inheritance when parental DNA was available 
(Table 1). We thereby identified recessive mutations in AVIL as a 
cause of recessive NS and introduce the term “NPHS25” for this 
variant of monogenic SRNS.
Location of and impact on structural flexibility of the mutations. 
Advillin (human Avil-1 [hAvil-1]) is a member of the gelsolin/
villin family of proteins and is most similar in sequence to vil-
lin. It shares the 6 gelsolin homology (GH) domains (Figure 2, A 
and B) with a number of other mammalian gelsolin/villin family 
members (Figure 2D), as well as the carboxyl terminal headpiece 
domain of villin. The 2 missense mutations (Arg135Gln and Leu-
425Met) are located in the interior of the GH2 and GH4 domains 
between the β-sheet and the long α-helix involved in actin bind-
ing (Figure 3A). In order to assess the impact on the structure 
and flexibility of the resulting mutant domains, we performed 
classical and scaled molecular dynamic (MD) simulations. The 
comparison of descriptors reflecting flexibility during the scaled 
MD simulations was indicative of dynamic changes between 
the WT and the mutated GH2 (Supplemental Figure 3, A–D) and 
GH4 domains (Supplemental Figure 3, E–H). These regions are 
mapped down on the overlay of the structures averaged over the 
trajectories of the WT domain and that of the mutant domains 
(Figure 3A). The Arg135Gln mutation in GH2 results in displace-
ment of the loop in between the first and second β strand. As the 
latter contains residues involved in the coordination of the cal-
cium ion at the type 2 site, this may in turn influence the abil-
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on the GH4 domain is involved in binding the actin filament, the 
mutation could therefore potentially affect the ability of hAvil-1 
to carry out its biological function. The Leu425Met mutation 
involves a change for leucine with a bulky, hydrophobic side 
chain to methionine, which is similarly long but less bulky and 
more polar in nature (Figure 3A).
135Gln mutation replaces a long, positively charged side chain 
with the shorter, polar but uncharged one of glutamine, with a 
propensity for the formation of hydrogen bonds rather than salt 
bridges (Figure 3A). According to scaled MD simulations, the 
Leu425Met mutation in GH4 correlates with a displacement of 
the C-terminal end of the actin-binding α helix. Since this α-helix 
Figure 2. WES identifies recessive mutations of AVIL in 3 families with SRNS. (A) Exon structure and functional domains of human AVIL cDNA. Positions 
of the start codon (ATG) and the stop codon (TAA) are indicated. Exons are marked on a black or white background. The length of protein domains is indi-
cated by colored boxes. The positions of mutations (family numbers are underlined) are lined up by black arrows in relation to exons and protein domains 
(see also Table 1). (B) Ribbon diagram of the atomic structure of advillin. The gelsolin domains labeled S1 to S6 are color-coded blue (S1), aqua (S2), green 
(S3), yellow (S4), orange (S5), and red (S6), with actin shown in gray (Protein Data Bank [PDB] references: 1H1V and 1RGI). (C) Chromatograms of AVIL 
variants identified in individuals with SRNS. Sequence traces are shown for the variants above normal controls. Arrowheads denote altered nucleotides. 
(D) Multiple amino acid sequence alignment of AVIL throughout evolution and multiple sequence alignment of the human AVIL paralogs VIL1, VILL, SCIN, 
GSN, FLII, and SVIL using the Clustal_O program.
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mental Figure 4, C and D). We found that AVIL was present in the 
F-actin–enriched cell periphery labeled with phalloidin that gener-
ates lamellipodia and focal adhesions (FAs) (Figure 3B). However, 
the truncating mutant construct of AVIL (Phe656Valfs*7) failed 
to localize with F-actin in podocytes (Figure 3B). To explore the 
deleteriousness of the AVIL mutations detected in individuals 
with SRNS, we generated the AVIL-truncating mutant constructs 
AVIL-Δ628-819 (deletion of the C-terminal S6 and HP domains) 
and AVIL-Δ135-143 (lacking one of the possible PIP2-binding 
motifs) (Supplemental Figure 5A). We found that GFP-tagged 
AVIL-Δ628-819 lacked localization with F-actin in podocytes, 
which is an equivalent to the mutant construct of AVIL (Phe-
656Valfs*7) (Supplemental Figure 5B).
The AVIL-truncating mutant lacks colocalization with F-actin. 
AVIL is known to be involved in neurite outgrowth and morpho-
genesis (20), but there is no information on its role in the kidney 
or podocytes. To study AVIL protein localization, we characterized 
2 different polyclonal antibodies directed against the N-terminus 
(α-AVIL-91606) and C-terminus (α-AVIL-80312) of AVIL (Sup-
plemental Figure 4, A and B). We demonstrated the presence of 
AVIL in protein extracts from cultured human podocytes (Supple-
mental Figure 4, A and B). Using immunoblotting, we found that 
α-AVIL-80312 recognized a band of 92 kDa (Supplemental Figure 
4B). To investigate subcellular localization of AVIL in podocytes, 
we performed immunofluorescence (IF) studies in a human podo-
cyte cell line upon overexpression of GFP-tagged AVIL (Supple-
Figure 3. Mutations in AVIL affect podocyte cytoskeleton architecture and inhibit the actin-bundling function of AVIL. (A) Locations of mutations in 
gelsolin homology domains of advillin and their effect on conformational flexibility. Overlay of averaged structures of WT (dark gray) and mutated GH2 
(blue) and GH4 (red) domains from MD studies of human AVIL (PDB references: 1RGI and 1H1V). Averaging was carried out over the whole scaled MD 
trajectory. A homology model for hAvil-1 was built using gelsolin as a template based on the crystal structures of actin-bound gelsolin 1H1V4 (S4–S6 or 
GH4–GH6 domains) (57) and 1RGI (S1–S3 or GH1–GH3 domains) (58). The models built served as starting structures for all MD studies. Structural elements 
with increased conformational flexibility are highlighted in teal and magenta for the GH2 domain and in yellow for the GH4 domain. Mutated residues are 
depicted with sticks, and spheres denote calcium ions. (B) Colocalization of AVIL with F-actin using cDNA clones representing WT and mutations detected 
in individuals with SRNS (Table 1). Human podocytes were transfected with GFP-tagged WT or the mutant AVIL (Arg135Gln, Leu425Met, or Phe 656Valfs*7) 
and were stained for F-actin with phalloidin (red). Colocalization of AVIL and phalloidin-labeled F-actin resulted in yellow fluorescence. Note that podo-
cytes with overexpression of the truncating mutant Phe656Valfs*7 lost the costaining pattern with phalloidin-labeled F-actin at the cell periphery (white 
arrowheads). Cell nuclei were stained with DAPI (blue). Scale bars: 10 μm. (C) For the actin-bundling assay, WT or mutant (Arg135Gln, Leu425Met, or Phe-
656Valfs*7) Avil GST proteins (1 μM) were incubated with F-actin. To determine actin bundling, samples were centrifuged at 10,000 g for 15 minutes, and 
actin distribution in supernatant (S) and pellet (P) fractions was analyzed by 10% SDS-PAGE and GelCode Blue staining. Control refers to F-actin filaments 
in the absence of Avil GST protein.
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Endogenous expression of AVIL in rat kidney glomeruli. We per-
formed immunofluorescence staining in 2-day-old rat kidney 
glomeruli, which showed that AVIL localized to the cytoplasm of 
podocytes in rat glomeruli (Supplemental Figure 6). We observed 
AVIL staining in cells positive for the podocyte marker WT1 in 
later stages of development of rat kidney glomeruli.
Mutations in AVIL inhibit its actin-regulatory functions. Like vil-
lin, gelsolin, and other members of actin-binding proteins, advillin 
has been described as playing an important role in F-actin polym-
erization (21). To further characterize the pathogenic effects of 
AVIL mutations detected in patients with SRNS, we studied the 
role of AVIL for actin-bundling,- binding, and -severing proper-
ties. Actin bundling was measured by low-speed centrifugation 
and sedimentation of bundled actin filaments. We found that WT 
AVIL protein bundled actin and that the majority of the actin fila-
ments appeared in the pellet (P) fraction (Figure 3C). However, in 
all 3 AVIL mutants (Arg135Gln, Leu425Met, and Phe656Valfs*7) 
that represented the mutations found in patients with SRNS, a 
majority of the actin filaments now appeared in the supernatant 
(S) fraction, demonstrating a severe defect in actin bundling.
We also tested whether the actin-binding and -severing func-
tions of AVIL were altered in its mutants. We examined the bind-
ing properties of AVIL by using a cosedimentation assay and found 
that only the truncating mutant of AVIL (Phe656Valfs*7) that lacks 
its F-actin–binding C-terminal domain showed a decrease in the 
binding affinity of AVIL for actin (Supplemental Figure 7A). Fur-
ther, we investigated the effect of mutant AVIL proteins on the 
actin-severing activity of advillin. Whereas the WT AVIL and 
2 mutants representing missense alleles showed normal actin- 
severing function, the truncating mutant exhibited a complete loss 
of the actin-severing ability of AVIL (Supplemental Figure 7B).
AVIL interacts with PLCE1 and the actin-related protein 2/3 
complex. We then delineated a comprehensive pathogenic axis of 
SRNS that integrates PLCE1 loss of function as follows: Immu-
nofluorescence staining of AVIL and paxillin, as a marker for FA 
(22), showed stronger AVIL localization at lamellipodia than at 
FAs (Figure 4A). It is well known that villin, a paralog of advillin 
(Figure 2D), interacts with phospholipase C γ1 (PLC-γ1) and regu-
lates PLC-γ1 catalytic activity, thus modifying phosphatidylino-
sitol signaling pathways (23). We previously demonstrated that 
PLCE1 mutations cause a form of SRNS that involves podocyte 
dysfunction (19). We therefore hypothesized that PLCE1, rather 
than PLCG1, may represent the phospholipase C isoform relevant 
for podocyte function and that advillin, rather than villin, may be 
activated by PLCE1 in podocytes (Supplemental Figure 1, A–C). 
Immunostaining for AVIL and PLCE1 revealed colocalization of 
both proteins at the cell periphery of human podocytes (Figure 
4A). This tight subcellular colocalization is consistent with defects 
of AVIL or PLCE1 causing monogenic recessive SRNS. Because of 
the colocalization of AVIL with F-actin in podocytes (Figure 3B), 
and because of the known role of AVIL in actin severing, which 
is a prerequisite for lamellipodia formation, we looked for AVIL 
colocalization with the actin-nucleating complex member actin- 
related protein 2/3 (ARP2/3), which has been shown to play a 
major role in dynamic actin assembly, especially in lamellipodia 
(24). AVIL and ARP3 colocalized at the podocyte periphery (Fig-
ure 4A), as we observed with F-actin (Figure 3B).
The observation that AVIL colocalized to the cell periphery 
with PLCE1 and ARP3 in a human podocyte cell line led us to 
perform co-IP studies to test for molecular interaction between 
AVIL and PLCE1 or ARP2/3. We found that AVIL coimmunopre-
cipitated with PLCE1 following cotransfection of Flag-tagged 
PLCE1 and GFP-tagged AVIL into HEK293T cells. We showed 
that the mutants Leu425Met and Phe656Valfs*7, reflecting the 
alleles found in the patients with NS, weakened this interaction 
(Figure 4B). We next tested the interaction of AVIL with Myc-
tagged ATCR2 (member of the ARP2 complex) (Figure 4C) and 
Myc-tagged ATCR3 (member of the ARP3 complex) (Figure 4D) 
by co-IP in HEK293T cells and observed that AVIL can form a pro-
tein complex with ARP2/3. We thereby implicated AVIL interac-
tion with PLCE1 and the ARP2/3 complex in podocyte function 
(Supplemental Figure 1, C–G).
Our findings integrate the pathogenic mechanisms of AVIL 
mutations with the function of PLCE1, F-actin, and the ARP com-
plex, all of which play a central role in podocyte lamellipodia for-
mation. To further determine the role of AVIL in podocyte func-
tion, we studied whether depletion of AVIL by shRNA knockdown 
would disrupt the actin cytoskeleton and podocyte morphology. 
We found that depletion of AVIL from human podocytes did not 
result in a significant change in podocyte morphology (Supple-
mental Figure 8 and Figure 4E), and FA still formed, as shown by 
α-actinin-4 (labeling the actin structure) and paxillin antibodies, 
respectively (Supplemental Figure 8, A and C). However, there 
were fewer formations of actin stress fibers and less abundance of 
paxillin at the podocyte lamellipodia following shRNA-mediated 
knockdown of AVIL compared with the scrambled shRNA nega-
tive control (Supplemental Figure 8, A and C, and Figure 4E). To 
confirm that the effect on actin stress fibers was specific to knock-
Figure 4. AVIL colocalizes with and interacts with PLCE1 and the ARP2/3 
complex. (A) Human podocytes transfected with a GFP-tagged, full-length 
(FL) mouse Avil construct were immunostained with mouse anti-paxillin 
(red), mouse anti-ARP3 (red), and rabbit anti-PLCE1 (red) antibodies, 
respectively. Note the colocalization of AVIL and ARP3 at podocyte lamel-
lipodia (empty white arrowheads) and the colocalization of AVIL and PLCE1 
at lamellipodia (solid white arrowheads). AVIL also overlapped with paxillin 
at FAs. Scale bars: 10 μm. Inset scale bars: 25 μm. (B) AVIL interacted with 
PLCE1 upon co-overexpression in HEK293T cells. GFP-tagged AVIL was 
co-overexpressed with Flag-tagged PLCE1 in HEK293T cells. Co-IP using 
Flag showed that GFP-tagged AVIL interacted with Flag-tagged PLCE1. 
(C and D) Upon co-overexpression in HEK293T cells, Myc-tagged ACTR2 
(ARP2 complex) (C) and ACTR3 (ARP3 complex) (D) interacted with GFP-
tagged AVIL. (E) Under EGF stimulation (100 ng/ml) in human cultured 
podocytes, PLCE1 (green) translocated to cell membrane ruffles, where it 
colocalized with ARP3 (red, solid white arrowheads). Cells depleted of AVIL 
by shRNA failed to recruit PLCE1 to the ARP-marked lamellipodia (empty 
white arrowheads) upon EGF stimulation. Scale bars: 10 μm. Inset scale 
bars: 25 μm. (F) Human podocytes were transfected with scrambled siRNA, 
siRNA-9, or siRNA-11 for AVIL. EGF stimulation increased the concentration 
of DAG in scrambled siRNA–treated control cells (black circles). siRNA-
mediated knockdown of AVIL decreased active DAG levels (pink circles). The 
overexpression of WT Avil rescued this effect (green circles), while the 3 
mutant clones (Arg135Gln, Leu425Met, and Phe656Valfs*7) from patients 
with SRNS did not (red circles). Individual data points were derived from 3 
independent experiments and are displayed as the mean and SD. Statistical 
analysis was performed using a 2-tailed, 1-way ANOVA [F (7,16) = 92.09,  
P < 0.0001]. ***P < 0.0001, by Sidak’s multiple comparisons test.
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altered PMR as an established intermediate phenotype of SRNS 
(Supplemental Figure 1, H and I).
Regulation of podocyte migration by interaction of AVIL with 
PLCE1. Next, we tested the mutual functional interaction of AVIL 
and PLCE1 with regard to PMR modulation. Both genes cause 
SRNS if mutated, and both proteins colocalized to lamellipodia 
in cultured human podocytes (Figure 4A). Interestingly, we found 
an increase in the PMR upon overexpression of human PLCE1 in 
human podocytes (Figure 5A). Furthermore, we observed that the 
decreased PMR upon knockdown of AVIL was rescued by overex-
pression of human PLCE1 (Figure 5C). In contrast, we found that 
the decreased PMR upon knockdown of PLCE1 was not rescued by 
overexpression of human AVIL (Figure 5D), indicating that PLCE1 
is downstream of AVIL in terms of PMR modulation, again con-
necting the SRNS-related pathogenesis of AVIL loss of function to 
PLCE1 (Supplemental Figure 1, H and I).
We then explored the effect of EGF on PMR modulation under 
AVIL or PLCE1 knockdown in human podocytes. EGF stimulation 
led to a marked increase in podocyte migration (Figure 5, C and 
D). The overexpression of human PLCE1 in AVIL-knockdown 
podocytes showed no additional effect after EGF stimulation 
(Figure 5C). This indicates that AVIL and PLCE1 are necessary for 
EGF-induced migration and are thus both downstream of PMR 
modulation by EGF (Supplemental Figure 1, C–I).
The ARP complex is a PMR effector downstream of EGF, AVIL, 
and PLCE1. As we found that AVIL colocalized and interacted with 
the ARP2/3 complex in actin-rich lamellipodia of the podocytes 
described above (Figure 4, B–D), we next assessed the effects 
of ARP2/3 complex inhibition on podocyte migration using the 
small-molecule inhibitor CK666, which binds at the interface 
of ARP2 and ARP3, thereby blocking their conversion into the 
active conformation (27). We found that CK666 treatment led to 
a marked PMR decrease (Figure 5E). Interestingly, the increase in 
the PMR upon AVIL or PLCE1 overexpression was abolished upon 
treatment with CK666 (Figure 5E). This strongly suggests that the 
PMR increase induced by AVIL or PLCE1 is dependent on ARP2/3 
complex activity. Furthermore, CK666 treatment blocked EGF-
induced migration in AVIL-knockdown cells (Figure 5F), demon-
strating that ARP2/3 function is downstream of PMR modulation 
by EGF, AVIL, and PLCE1 (Supplemental Figure 1, F–I).
Discussion
In this study, we have identified recessive mutations in advillin 
(AVIL) as a single-gene cause of SRNS. We describe how AVIL 
mutations result in a defective PMR as an intermediate phenotype 
of SRNS and elucidate the role of EGF signaling, PLCE1 recruit-
ment by AVIL, IP3 and DAG generation by PLCE1, actin bundling 
by AVIL, and assembly of the ARP2/3 complex to form podocyte 
lamellipodia (Supplemental Figure 1).
Advillin is similar to other members of the gelsolin/villin fam-
ily and is most similar to villin in terms of sequence. It shares the 
6-domain gelsolin structure (Figure 2, A and B) with a number of 
other mammalian gelsolin/villin family members (Figure 2D), as 
well as the carboxyl terminal headpiece domain of villin. Gelso-
lin/villin proteins have been shown to serve important functions 
in regulating the actin organization. Here, we studied and charac-
terized the role of AVIL for actin-bundling, -binding, and -sever-
down of AVIL, we performed siRNA-mediated knockdown of 
NUP107, a known monogenic cause of SRNS (25), in human podo-
cytes and observed no effect on stress fibers compared with the 
scrambled siRNA–knockdown control (Supplemental Figure 8B). 
Upon stimulation with EGF, PLCE1 translocated to the lamellipo-
dia (as described in ref. 26), where it colocalized with ARP3 (Figure 
4E and Supplemental Figure 8D). Interestingly, depletion of AVIL 
from podocytes failed to recruit PLCE1 to the ARP3-rich region, 
which marks the formation of lamellipodia upon EGF stimulation 
(Figure 4E and Supplemental Figure 8D). We confirmed the effi-
ciency of knockdown by shRNA in podocytes by immunoblotting 
using an anti-advillin antibody (Supplemental Figure 4B). The 
results indicated that AVIL plays a role in lamellipodia formation 
through the ARP2/3 complex (Supplemental Figure 1, F and G).
EGF-induced diacylglycerol generation by phospholipase C ϵ1 
activity is blocked by AVIL knockdown. PLCE1 is a member of the 
phospholipase family of enzymes that catalyzes the hydrolysis of 
polyphosphoinositides to generate the second messengers ino-
sitol-1,4,5 trisphosphate (IP3) and diacylglycerol (DAG) (19). Our 
group has previously demonstrated that PLCE1 causes SRNS (19). 
In addition, it is well known that villin, a paralog of advillin (Figure 
2D), interacts with PLC-γ1 and regulates PLC-γ1 catalytic activ-
ity, thus modifying phosphatidylinositol signaling pathways (23). 
We therefore hypothesized that PLCE1, rather than PLCG1, may 
represent the PLC isoform relevant for podocyte function and 
that advillin, rather than villin, may be the relevant activator of 
podocytes. We tested and confirmed the interaction of AVIL with 
PLCE1 and delineated a pathogenic axis in SRNS that integrates 
AVIL loss of function with the established role of the SRNS protein 
PLCE1 (Supplemental Figure 1). Next, we measured the effect of 
AVIL knockdown on the levels of EGF-induced DAG generated by 
PLCE1 in human cultured podocytes and found that upon knock-
down of AVIL, DAG levels where reduced, even after stimulation 
with EGF. This effect was found to be reversed when WT mouse 
Avil was transfected into human podocytes (Figure 4F). In contrast, 
all 3 AVIL mutants (Arg135Gln, Leu425Met, and Phe656Valfs*7), 
detected in patients with NS, failed to fully rescue the decreased 
DAG levels (Figure 4F), thereby connecting the pathogenesis of 
AVIL mutations to the loss of function of DAG generation by the 
SRNS-related protein PLCE1 (Supplemental Figure 1, D and E).
AVIL mutations lack modulation of the PMR. We next exam-
ined the effect of AVIL on the PMR, which represents a relevant 
intermediate cellular phenotype in many forms of monogenic 
SRNS (8, 10, 12). We used the IncuCyte ZOOM video microscopy 
system, which monitors cell migration in real time. We observed 
an increase in the PMR upon overexpression of mouse Avil or 
human PLCE1 in human podocytes (Figure 5A). In contrast, the 
AVIL construct representing mutations detected in individuals 
with SRNS failed to increase the PMR (Figure 5A). Furthermore, 
we observed a PMR decrease after shRNA-mediated knockdown 
of AVIL in cultured human podocytes (Figure 5B). Interestingly, 
the PMR decrease upon knockdown of AVIL was reversed by 
overexpression of WT mouse Avil. In contrast, overexpression of 
Avil-mutant constructs that represented the mutations found in 
patients with SRNS (Arg135Gln, Leu425Met, and Phe656Valfs*7) 
failed to rescue the reduction in the PMR caused by AVIL knock-
down (Figure 5B). We thereby connected AVIL loss of function to 
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Figure 5. The ARP complex is an effector for podocyte migration downstream of EGF, AVIL, and PLCE1. (A) Human podocytes transfected with WT Avil 
(green) or PLCE1 (blue) showed a significant increase in the PMR compared with mock (black). Overexpression of Avil mutants failed to increase the PMR. 
Mutations: Arg135Gln (red triangle dotted line), Leu425Met (red rhombus solid line), and Phe656Valfs*7 (red cross dotted line). (B) Knockdown of AVIL 
(pink) showed a strongly reduced PMR compared with scrambled shRNA (black), which was partially rescued by overexpression of WT Avil (green) but not 
by mutants. (C) EGF stimulation increased the PMR in scrambled shRNA (black solid line). The PMR reduction upon AVIL knockdown (pink dotted line) 
was partially rescued by EGF treatment (pink solid line), but overexpression of PLCE1 (blue dotted line) showed no additional rescue effect over EGF (blue 
solid line). (D) The PMR reduction upon PLCE1 knockdown (turquoise dotted line) was partially rescued by EGF (turquoise solid line). Overexpression of 
AVIL (green dotted line) failed to rescue the PMR reduction in PLCE1-knockdown cells (turquoise dotted line). Overexpression of Avil showed no additional 
rescue effect over EGF treatment (green solid line). (E) Human podocytes transfected with the scrambled control showed a decreased PMR upon treat-
ment with the ARP inhibitor CK666 (black solid line) compared with the scrambled control without CK666 treatment (black dotted line). The PMR increase 
upon overexpression of WT Avil (green dotted line) or PLCE1 (blue dotted line) was blocked by the addition of CK666 (green or blue solid lines, respectively). 
(F) Human podocytes were pretreated with CK666 for 45 minutes before the wound scratch was performed. Migration assays with scrambled shRNA as 
a negative control were conducted with (gray solid line) or without (black dotted line) EGF stimulation following the wound scratch in podocytes. The 
reduction in PMR upon AVIL knockdown (pink dotted line) was rescued by EGF (green solid line), but was not rescued in the presence of CK666 (brown solid 
line). The relative migration rate and wound density (percentage) were calculated by IncuCyte assay. Multiple scratch wounds were made in confluent cells. 
Scratch wounds were allowed to heal for 24 hours, and the PMR was plotted on graphs.
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GENEHUNTER 2.1 (32, 33) with stepwise use of a sliding window with 
sets of 110 SNPs and the program ALLEGRO (33) to identify regions of 
homozygosity, as described previously (14, 34), using a disease allele 
frequency of 0.0001 and Caucasian marker allele frequencies.
WES and mutation calling. WES and variant burden analysis were 
performed as described previously (35).
High-throughput mutation analysis using array-based multiplex 
PCR and NGS. We used PCR-based 48.48 Access Array microfluidic 
technology (Fluidigm) with consecutive NGS. A 12-fold primer multi-
plexing approach was applied, allowing PCR-based amplification for 
48 DNA samples simultaneously in 576 amplicons (16). A total of 800 
individuals with SRNS were analyzed. The primer sequences for tar-
geted exon sequencing are provided in Supplemental Table 2.
cDNA cloning. A mouse Avil full-length cDNA was subcloned 
by PCR from mouse full-length cDNA (clone 40129468, catalog 
MMM1013-211691434; Thermo Fisher Scientific). Human full-length 
cDNA was subcloned from a full-length human AVIL cDNA clone 
purchased from Open Biosystems (BC111730). Three variations to 
the human reference sequence (NM_009635.3) were corrected by 
mutagenesis using the QuikChange II XL Site-Directed Mutagenesis 
Kit (Agilent Technologies). A human PLCE1 construct was created as 
described previously (19). Expression constructs (pGEX4T-3, pRK5-
N-Myc, pCDNA6.2-N-GFP, pCS-Dest2, and pSirenRetroQ) were pro-
duced using LR Clonase (Invitrogen, Thermo Fisher Scientific) follow-
ing the manufacturer’s instructions.
TA cloning. In the case of A913_21, two SNPs (c.940-88G>T and 
c.1672-1161T>G) were found between the two mutations c.404G>A 
and c.1964dupT in the AVIL gene. By designing the primers for nested 
PCR, 3 products were amplified from genomic DNA, gel-purified, 
ligated by means of a TA ligation method into the TA-cloning vec-
tor pGEM-T (Promega), and subcloned into E. coli DH5α–competent 
cells (Invitrogen, Thermo Fisher Scientific) using standard proce-
dures. The plasmid inserts were sequenced using the forward T7 and 
SP6 primers. DNA from 10 to 15 independent clones was sequenced. 
WT and mutated sequences were compared manually. The primer 
sequences for nested PCR were as follows: P1.1, AGTGAGGCTG-
CATCTGTGTAATT; P1.2, GATGTTCCCTTAGCTACAAGCAGG; 
P1.3, CATTCCCAAAGGCAGGTCAGT; P1.4, ATCGTTGACG-
GTCTCCACATT; P2.1, CACCGCAAGCCAATAAACAGAT; P2.2, 
CTTGGTCCTTAGACAAAAGTGAGTTAGA; P2.3, CAACATG-
GCGAAACCTCGTCT; P2.4, CAGGAGTAGGATTGCTGGATCA; 
P3.1, CATCATTAGTCACTAGGGAGATGCA; P3.2, TGACAACATA-
AAATATGAGCAAGGATGC; 3.3, GTGCAGGTACTGCTGTGCT; and 
P3.4, CTGTGAAGATGGGAGGCTCAAAC.
Computational methods for MD. The automatic model-building 
search for a structural template was carried out against the SWISS-
MODEL template library (SMTL, update: 2015-04.01) using BLAST 
(36) and HHbit (37) for evolutionarily related structures matching 
the target sequence. The template was selected on the basis of qual-
ity assessment using the QMEAN scoring function (38). Multiple 
sequence alignment was performed using Promod-II16. The template 
selected was the x-ray structure of gelsolin solved at 2.80 Å resolution 
(2FGH, chain A). The sequence covered 88% of the modeled struc-
ture, with 43% sequence similarity and 46.11% sequence identity.
Model building. Manual multiple sequence alignment was car-
ried out using ClustalX (39). Homology models were built with Mod-
eller 9.16 (40) using the Chimera interface (41). The sequence iden-
ing properties. We demonstrate the involvement and role of AVIL 
in actin dynamics and further characterize the pathogenic effects 
of AVIL mutations that were detected in individuals with SRNS. 
Interestingly, we found that, while all AVIL mutants showed a 
significant loss of its actin-bundling ability, the AVIL-truncating 
mutation also disrupted colocalization with F-actin and showed 
impaired actin-binding and -severing function.
PLCE1, a known NS-causing gene if mutated, is a member of 
the phospholipase family of enzymes that catalyzes the hydrolysis 
of polyphosphoinositides to generate the second messengers IP3 
and DAG (Supplemental Figure 1). DAG regulates the release of 
calcium from intracellular stores (19), thereby initiating actin sev-
ering, which is a prerequisite for actin nucleation by the ARP2/3 
complex and a prerequisite for lamellipodia formation and podo-
cyte migration (Supplemental Figure 1, D–I). PLCE1, linked with 
second messengers and the small Rho-like GTPases, has been 
helpful in identifying the pathogenic pathway in SRNS (Supple-
mental Figure 1). We confirmed that AVIL interacts and colo-
calizes with PLCE1 in human podocytes. Furthermore, we also 
found that AVIL interacts with ARP2/3 and colocalizes with it at 
the podocyte periphery.
We explored the effect of AVIL on the PMR, which repre-
sents a relevant intermediate cellular phenotype in many forms 
of monogenic SRNS. Interestingly, we found that EGF stimulation 
increased the PMR, which was partially diminished by knock-
down of the SRNS-causing gene AVIL or PLCE1. In addition, the 
PMR increase caused by overexpression of AVIL or PLCE1 or by 
EGF stimulation was abolished by the ARP2/3 complex inhibitor 
CK666, indicating that ARP-dependent lamellipodia formation 
occurs downstream of AVIL or PLCE1 function.
To test whether the knockdown of Avil in zebrafish results 
in a renal phenotype, we also generated a CRISPR model of Avil 
knockdown in zebrafish, but our initial experiments did not show 
a larval edema phenotype. However, virtually the entire literature 
on zebrafish models for NS has been based on morpholino oligo-
nucleotide (MO) knockdown in zebrafish larvae. This includes the 
genes PLCE1 (19), ADCK4 (28), ARHGDIA (8), and EMP2 (29). 
And it is of note that the approach of morpholino-based knock-
down of genes in zebrafish disease models has been recently ques-
tioned in a major way, because these data were not reproducible in 
mutant stable lines (30). Therefore, we currently do not expect to 
be able to easily generate a zebrafish model for NS.
In summary, we have delineated a complete pathogenic axis 
in SRNS that integrates AVIL loss of function with the role of the 
established SRNS protein PLCE1. Multiple components of this 
pathogenic axis may represent drug targets for SRNS, for which no 
efficient treatment exists.
Methods
Research subjects. We obtained blood samples and pedigrees after obtain-
ing informed consent from individuals with NS. The diagnoses of NS 
and SRNS were based on published clinical criteria and renal biopsies 
criteria evaluated by renal pathologists (31). Clinical data were obtained 
using a standardized questionnaire (http://www.renalgenes.org).
Linkage analysis. For genome-wide HM, the GeneChip Human 
Mapping 250k StyI Array from Affymetrix was used. Nonparametric 
lod scores were calculated using a modified version of the program 
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-binding, and -severing assays were performed as described previous-
ly (52, 53). Fluorescence measurements were performed at 25°C using 
the FluoroMax 3 spectrofluorometer (Horiba Scientific).
Cell lines. The experiments described here were performed 
using HEK293T cells and immortalized human podocytes. 
HEK293T cells were purchased from the ATCC Biological Resource 
Center. Human immortalized podocytes were a gift of Moin Saleem 
(University of Bristol, Bristol, United Kingdom) and were cultured 
as previously described (54).
siRNA and shRNA transfection. For some knockdown experiments, 
cells were transfected with ON-TARGET siRNA against AVIL (GE 
Dharmacon) at a final concentration of 100 nM using Lipofectamine 
RNAiMAX (Thermo Fisher Scientific) according to the manufacturers’ 
instructions. Experiments were performed 48 hours after transfection. 
Additionally, shRNA against human AVIL and PLCE1 was subcloned 
into pSIREN RetroQ for retroviral transduction using HEK293T cells. 
Forty-eight hours after transduction, puromycin at a final concentra-
tion of 4 μg/ml was added to the medium for selection of transduced 
cells. See Supplemental Table 2 for the list of target sequences.
Reagents and antibodies. For immunofluorescence experiments, 
the following primary antibodies were used: rabbit anti-AVIL (NBP-
80312; Novus Biologicals); rabbit anti-PLCE1 (CS117) (19); mouse 
anti–α–actinin-4 (sc393495; Santa Cruz Biotechnology); mouse anti-
paxillin (610619; BD); mouse anti-Arp3 (ab49671; Abcam); and anti-
WT1 (sc-7385; Santa Cruz Biotechnology). Donkey anti-goat Alexa 
488– and Alexa 594–conjugated secondary antibodies and DAPI were 
obtained from Invitrogen (Thermo Fisher Scientific). For immunob-
lotting, the following primary antibodies were used: rabbit anti-AVIL 
(NBP-91606; Novus Biologicals); rabbit anti-AVIL (NBP-80312; Novus 
Biologicals); rabbit anti-PLCE1 (LS-C152751; Cell Signaling Technol-
ogy); and rabbit anti-PLCE1 (CS117), which has been described pre-
viously (19). HRP-labeled secondary antibodies were purchased from 
Santa Cruz Biotechnology. For cell treatment, the following reagents 
were used: EGF recombinant human protein (Life Technologies, Ther-
mo Fisher Scientific); ROCK inhibitor (Y-27632; Cytoskeleton); and 
ARP2/3 complex inhibitor I (CK666; Calbiochem).
Immunofluorescence and confocal microscopy in cell lines and tissue 
sections. For immuno-staining, human immortalized podocytes were 
seeded on coverglasses and grown at a permissive temperature. For 
overexpression studies, human podocytes were transiently trans-
fected using Lipofectamine 2000 (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions. Experiments were performed 
24–48 hours after transfection. Cells were fixed and permeabilized for 
10 minutes using 4% paraformaldehyde and 0.01% SDS. After block-
ing, cells were incubated overnight at 4°C. The cells were incubated in 
secondary antibodies for 90 minutes at room temperature, followed 
by 5 minutes of staining with 1× DAPI and PBS. For immunostaining 
of paraffin-embedded tissue sections (rat kidney, day 2 postpartum), 
permeabilization was performed using 0.025% Triton-X 100. Con-
focal imaging was performed using the Leica SP5X system with an 
upright DM6000 microscope, and images were processed with the 
Leica AF software suite.
Co-IP. Co-IP experiments were performed as described previous-
ly (55). Briefly, cell lysates were precleared with protein G or A beads. 
Next, cell lysates were mixed with the appropriate antibodies and 
incubated overnight at 4°C in lysis buffer containing the complete pro-
tease inhibitor mixture. Immune complexes were collected by binding 
tity was calculated in the Multiple Alignment Viewer of Chimera. For 
modeling of the gelsolin domain–containing part of hAvil-1 (without 
the headpiece), the crystal structures of 1H1V, 1RGI, and 3FFK were 
used. 1RGI and 3FFK covered the GH1-3 part of hAvil-1 (48.82% and 
48.40% sequence identity, respectively), while 1H1V covered the 
GH4-GH6 part (48.62% sequence identity). No attempt was made to 
model the headpiece domain. The 1H1V chain G structure was used 
as a template to build the model of the individual GH4 domain. The 
sequence of 1H1V covered 100% of the modeled GH4 domain, with 
48.63% sequence identity and 23.35% sequence similarity. The 1RGI 
crystal structure was used as a template for the GH2 domain model. 
The sequence of 1RGI covered the whole GH2 domain, with 46.24% 
sequence identity and 23.6% sequence similarity. For modeling of 
the GH4 domain, the sequence between residues 391 and 504 of the 
built model was used, producing a 114-residue-long construct. Two 
calcium ions were positioned at the same coordinates as in 1H1V.pdb. 
For the GH2 domain model, the construct contained residues between 
134 and 226. The GH2 domain contains 1 calcium ion, which was posi-
tioned at the same location as in 1RGI.
MD. All MD simulations were performed using AMBER version 
14, implemented for GPUs (42). The AMBER ff99SB force field (43) 
for the peptides and the TIP3P model (44) for water were used. The 
cutoff used for nonbonded interactions was 8 Å. The particle-mesh 
Ewald (45) procedure was used to describe long-range electrostatic 
interactions with maximal grid spacing of 1 Å. Periodic boundary 
conditions were applied using truncated octahedron geometry. The 
SHAKE (46) algorithm was used to keep the bond lengths of hydrogen 
atoms rigid, thus allowing a time step of 2 fs to be used. The protocol 
for constant temperature and constant pressure (NPT) simulations 
started with minimization in 2,000 steps, switching from the steepest 
descent to conjugate the gradient algorithm after 1,000 steps. After 
minimization, a constant energy/constant volume (NVE ensemble) 
MD was carried out for 50 ps while increasing the temperature from 
0°K to 50°K. The system was further relaxed in a 1-ns-long MD sim-
ulation using NPT ensemble while increasing the temperature from 
50°K to 310°K over a 500-ps period and keeping it at this tempera-
ture for 500 ps. During both relaxation steps, backbone atoms were 
restrained with a 4 kcal/mol/Å force constant. Subsequently, a third 
relaxation step was conducted at 310°K and 1 bar pressure using an 
NPT ensemble for 1 ns without restraints. A 200-ns classical MD-pro-
ducing canonical NPT ensemble was carried out at 310°K and 1 bar. 
Both NPT ensembles were performed using temperature regulation 
with Langevin dynamics, with a collision frequency of 1 ps–1 and appli-
cation of isotropic pressure scaling with a pressure relaxation time of 
1 ps. Protocols identical to those for scaled MD (47) were used for the 
NPT simulations to produce a 100-ns-long trajectory with a scaling 
factor of 0.7. Analysis 50000 coordinate snapshots were saved for 
analysis in all cases. Order parameters for the NH bond vectors of each 
residue were extracted using Isotropic Reorientational Eigenmode 
Dynamics (iRED) analysis (48). The trajectories were analyzed with 
cpptraj29 (49) and visualized in VMD (50). Visualization and analysis 
of the molecules were done in the PyMOL Molecular Graphics System, 
version 1.8 (Schrodinger, LLC).
Measurement of actin-bundling, -binding, and -severing activities 
of advillin. Human WT AVIL and AVIL mutants were cloned into a 
pGEX-4T-3 GST vector, and GST-tagged (recombinant) protein was 
generated and purified (51) (Supplemental Figure 9). Actin-bundling, 
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age, performed exome capture and massively parallel sequencing, 
and performed whole-exome evaluation and mutation analyses. 
JR, SA, SPG, AE, and SK performed cDNA cloning, protein puri-
fication and immunofluorescence, and subcellular localization 
studies in cell lines by confocal microscopy. JR performed migra-
tion assays in immortalized human podocytes. SA performed co-IP 
experiments and measurement of DAG levels. KF, JCM, and MAJ 
performed and analyzed MD simulation experiments. SPG, AE, 
and SK performed actin-bundling, -binding, and-severing assays. 
AN, MS, YT, MB, UH, S. Mir, A. Berdeli, JAK, SED, NAS, A. Bagga, 
and FH recruited patients and gathered detailed clinical informa-
tion for the study. FH conceived the study. JR, SA, and FH wrote 
the manuscript, which was critically reviewed by all the authors.
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